

Applicant: Erik Buntinx  
Serial No.: 10/725,965  
Filed: December 2, 2003  
page 2 of 2

REMARKS

In the Information Disclosure Statement submitted on December 10, 2009, applicant enclosed a copy of the Wade et al. 2009 online Abstract submission, which reported that a very low daily dose of pipamperone (5 mg) added to citalopram (40 mg) provided superior antidepressant effects and fewer discontinuations compared with citalopram alone. Applicant encloses with the present reply and Information Disclosure Statement a copy of the Wade et al. poster presentation of the previously provided Abstract. The poster was presented on December 9, 2009 at the American College of Neuropsychopharmacology (ACNP) meeting in Hollywood, Florida.

No fee is deemed necessary in connection with the filing of this response. However, if any fee is required to preserve the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: December 30, 2009  
New York, New York

By /Alan D. Miller/  
Alan D. Miller, Reg. No. 42,889